[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse RAB31

Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, trans-Golgi network Golgi apparatus, trans-Golgi network membrane Lipid-anchor Cytoplasmic side Early endosome Cytoplasmic vesicle, phagosome Cytoplasmic vesicle, phagosome membrane Lipid-anchor Cytoplasmic side Note=Rapidly recruited to phagosomes containing S.aureus or M.tuberculosis (PubMed:21255211).
Domain PF00071 Ras family
Function

The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. Required for the integrity and for normal function of the Golgi apparatus and the trans-Golgi network. Plays a role in insulin-stimulated translocation of GLUT4 to the cell membrane. Plays a role in M6PR transport from the trans-Golgi network to endosomes. Plays a role in the internalization of EGFR from the cell membrane into endosomes. Plays a role in the maturation of phagosomes that engulf pathogens, such as S.aureus and M.tuberculosis.

> Gene Ontology
 
Biological Process GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0007009 plasma membrane organization
GO:0031623 receptor internalization
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0043001 Golgi to plasma membrane protein transport
GO:0043112 receptor metabolic process
GO:0043434 response to peptide hormone
GO:0045055 regulated exocytosis
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090382 phagosome maturation
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1990778 protein localization to cell periphery
Molecular Function GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0019003 GDP binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component GO:0005769 early endosome
GO:0005802 trans-Golgi network
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030670 phagocytic vesicle membrane
GO:0031984 organelle subcompartment
GO:0032588 trans-Golgi network membrane
GO:0045335 phagocytic vesicle
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-8876198: RAB GEFs exchange GTP for GDP on RABs
R-HSA-8873719: RAB geranylgeranylation
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RAB31 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RAB31 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RAB31 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1670.00391
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2280.554
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1180.448
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5070.164
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0140.451
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1350.938
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2970.585
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1550.932
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4640.819
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9820.523
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.60.499
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2320.0896
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RAB31 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAB31. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAB31. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAB31.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAB31. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RAB31 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RAB31 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRAB31
NameRAB31, member RAS oncogene family
Aliases Rab22B; ras-related protein Rab-22B; Ras-related protein Rab-31
Chromosomal Location18p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RAB31 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.